Is transperineal biopsy ready to be used at the same capacity as transrectal biopsy?
“There was a point when people thought a trial [would] not be necessary because the answers [were] so clear cut. But obviously, more than just 1 person feels that these are not so clear-cut answers,” says Badar M. Mian, MD, FACS.
In this video, Badar M. Mian, MD, FACS, discusses what is to come for transperineal biopsy in regard to integrating this modality into the current standard of care for patients with prostate cancer. Mian is a professor of surgery and urology at Albany Med Urology in Albany, New York.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
